• Like
3.1 francois dabis
Upcoming SlideShare
Loading in...5
×
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
523
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
17
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • Cumulative mortality over four years reaches 15% in Africa and 5% in Europe and North America. Note the rapid increase in cumulative mortality in the first months in sub-Saharan Africa, a phenomenon not seen in the data from industrialized settings.

Transcript

  • 1. Tackling infectious diseases French-based international research networks François Dabis CEA CHRU CNRS CPU INRA INRIA INSERM INSTITUT PASTEUR IRD
  • 2. Infectious diseases: 2/3 of all deaths in children <5 years Black RE – Lancet 2010 18% 15% 31%
  • 3. The French-based international infectious diseases research networks
  • 4. 4 networks of excellence active in most of the developing world
  • 5. 9 Institutes Respiratory Infections Encephalitis HIV/AIDS Hepatitis Zoonosis Dengue Malaria Research tools Microorganism culture Biobank/Databank Surveillance Cohorts Entomology Priority areas Public health reference labs Research Training Asia-Pacific Region
  • 6. The HIV/AIDS pandemic significant challenges Pressing need to increase research efforts in prevention and care 34 million of people living with HIV worldwide in 2010 2.6 million new HIV infections in 2010 only (7 000 / day) 1.4 million have started antiretroviral treatment in 2010
  • 7. Low 4-year mortality on antiretroviral treatment is achievable in developing countries (Lancet 2006) sub-Saharan Africa (ART-LINC ) 18 cohorts 4,810 pts Europe & North America (ART-CC) Risk of death (%)
  • 8. Lowering the risk of mother-to-child transmission of HIV in pregnant women Côte d’Ivoire ANRS experience (Lancet 1999, AIDS 2005, PLoS Medicine 2007)
  • 9. From animal model to phase I/II (safety, pk, viral resistance) in Cambodia, Côte d’Ivoire and South Africa Prevention of Mother-to-Child Transmission of HIV Antimicrob Agents Chemother 2009, 2011 a, b, c, d AIDS 2009, 2010 Clin Pharmacol Ther 2009
  • 10. Antiretrovirals for the prevention of mother-to-child transmission of HIV from phase I/II to WHO guidelines
  • 11. Toward elimination of pediatric HIV infection by 2015
  • 12. Perspectives
      • Public/private investments from basic to translational research:
      • Multidisciplinary
      • Using existing networks
      • Classic and emerging pathogens
  • 13. Perspectives
      • (2) Public/private partnerships
      • should include phase IV
      • and pharmaco-epidemiology
  • 14. Perspectives
      • (3) A viable market
    Deauville, May 26-27, 2011 (VI / 60) G8 encourages drug companies to work with Medicines Patent Pool and welcomes the development of AMC